Evotec SE (EVO) Amortization - Intangibles (2009 - 2023)

Evotec SE (EVO) posted Amortization - Intangibles of -$5520.6 for Q4 2023, down 571.19% sequentially from -$822.52 in Q2 2021.

Evotec SE (EVO) Amortization - Intangibles (2009 - 2023) Analysis & Trends

Evotec SE has reported Amortization - Intangibles for 3 years, with the latest figure at -$5520.6 in Q4 2023.

Quarterly Amortization - Intangibles changed N/A year-over-year to -$5520.6 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $26.8 million (changed N/A YoY) and the FY2023 annual result came in at -$5520.6, changed N/A from the prior year.
Amortization - Intangibles eased to -$5520.6 in Q4 2023 per EVO's latest filing, from -$822.52 in the prior quarter.
Over five years, Amortization - Intangibles peaked at -$822.52 in Q2 2021 and troughed at -$5520.6 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-
10	Evotec SE	681.90 Mn	681.42 Mn	-

Download Data